# US 7,449,323 B2 · Hemorrhagic feline calicivirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,449,323 B2
- Document ID: US7449323B2
- Status: Granted
- Kind: B2
- Application number: 11/939,480
- Filed: 2007-11-13
- Published: 2008-03-13
- Granted: 2008-11-11
- Earliest claimed: 2003-03-14
- Assignees: The Regents of the University of California
- Inventors: Janet E. Foley; Kate Hurley; Niels C. Pedersen
- Web page: https://patentgrep.com/patent/US7449323B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61K 39/125: Picornaviridae, e.g. calicivirus
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2770/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/16061: Methods of inactivation or attenuation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a vaccine for immunization against a viral infection caused by a hemorrhagic feline calicivirus (hFCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of hFCV.

## Claims

### Claim 1

A method of immunizing a cat against a hemorrhagic feline calicivirus (hFCV) which comprises administering to said cat an immunologically effective dose of a composition comprising a physiologically acceptable carrier and an attenuated, killed or inactivated hFCV, wherein the hFCV, prior to attenuation, killing, or inactivation, has all the distinguishing characteristics of a virus deposited under ATCC Accession Number PTA-5798 or PTA-5797, wherein the distinguishing characteristics comprise inducing a hemorrhagic fever syndrome in cats, and inducing a cytopathic effect against Crandell feline kidney cells in the presence of anti-FCV-F9 antiserum at a dilution of 1:16 or less.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition comprises an adjuvant.

### Claim 3 (depends on 1)

The method of claim 1, wherein said administering is selected from the group consisting of oronasally, subcutaneously, and intramuscularly.